Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.45 |
| ▸ | RELA | Q04206 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988919 | 0.88 | NFKB1 (0.54) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL23646375 | 0.88 | BTK (0.49) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL25393763 | 0.86 | BTK (0.48) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL9114891 | 0.86 | NFKB1 (0.44) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL9114887 | 0.86 | NFKB1 (0.44) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL9114899 | 0.86 | NFKB1 (0.44) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL16976712 | 0.83 | NFKB1 (0.50) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL13678772 | 0.83 | BTK (0.47) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL1012695 | 0.83 | BTK (0.47) | BTKNFKB1NFKB2RELAGAA | |
| SCHEMBL1030494 | 0.83 | BTK (0.47) | BTKNFKB1NFKB2RELAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | BTK 3308/4885NFKB1 2029/4885NFKB2 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.